U.S. patent application number 10/675982 was filed with the patent office on 2005-03-17 for modifided carboxypeptidase enzymes and their use.
This patent application is currently assigned to Cancer Research Technology Limited. Invention is credited to Begent, Richard H.J., Chester, Kerry, Minton, Nigel P., Rees, Anthony R., Sharma, Surinder K., Spencer, Daniel I. R..
Application Number | 20050059133 10/675982 |
Document ID | / |
Family ID | 26911249 |
Filed Date | 2005-03-17 |
United States Patent
Application |
20050059133 |
Kind Code |
A1 |
Begent, Richard H.J. ; et
al. |
March 17, 2005 |
Modifided carboxypeptidase enzymes and their use
Abstract
The invention relates to improvements relating to cancer therapy
based on the identification of a number of regions of CPG2 which
contain epitopes which appear to be involved in the production of a
host immune response and which may be modified to alter the
immunogenicity in patients. Production of fusions of CPG2 with an
antibody, where the CPG2 protein has been tagged provides a CPG2
protein which has reduced immunogenicity. By using partially
glycosylated enzyme obtainable by P. pastoris expression, the
efficacy of antibody-CPG2 fusions is enhanced.
Inventors: |
Begent, Richard H.J.;
(London, GB) ; Chester, Kerry; (London, GB)
; Minton, Nigel P.; (Wiltshire, GB) ; Rees,
Anthony R.; (Bath, GB) ; Sharma, Surinder K.;
(London, GB) ; Spencer, Daniel I. R.;
(Hertfordshire, GB) |
Correspondence
Address: |
NIXON & VANDERHYE, PC
1100 N GLEBE ROAD
8TH FLOOR
ARLINGTON
VA
22201-4714
US
|
Assignee: |
Cancer Research Technology
Limited
London
GB
|
Family ID: |
26911249 |
Appl. No.: |
10/675982 |
Filed: |
October 2, 2003 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10675982 |
Oct 2, 2003 |
|
|
|
09898461 |
Jul 5, 2001 |
|
|
|
6656718 |
|
|
|
|
60216689 |
Jul 7, 2000 |
|
|
|
Current U.S.
Class: |
435/220 ;
435/252.34; 435/320.1; 435/69.1; 536/23.2 |
Current CPC
Class: |
C07K 2319/00 20130101;
C12N 9/48 20130101 |
Class at
Publication: |
435/220 ;
435/069.1; 435/252.34; 435/320.1; 536/023.2 |
International
Class: |
C12N 009/52; C07H
021/04; C12N 001/21; C12N 015/74 |
Claims
1-15. (Canceled)
16. An isolated carboxypeptidease enzyme, CPG2, in which an
immunogenic region is modified to reduce immunogenicity to a
mammalian immune system whilst retaining CPG2 activity, wherein the
immunogenic region is selected from the group consisting of:
4 (i) KIDGRGGK (SEQ ID NO.1) comprising residues 98-105 of SEQ ID
NO.7; (ii) KEYGVRD (SEQ ID NO.2) comprising residues 157-163 of SEQ
ID NO.7; (iii) YGVRD (SEQ ID NO.6) comprising residues 159-163 of
SEQ ID NO.7; (iv) KLADY (SEQ ID NO.3) comprising residues 191-195
of SEQ ID NO.7; (v) GAGK (SEQ ID NO.4) comprising residues 412 to
the C-terminal residue 415 of SEQ ID NO.7; (vi) AG comprising
residues 413-414 of SEQ ID NO.7; and (vii) EGGKKLVDK (SEQ ID NO.5)
comprising residues 331-339 of SEQ ID NO.7.
17. An isolated or purified Pseudomonas carboxypeptidase CPG2
enzyme wherein the C-terminus of the enzyme comprises an extension
selected from the group consisting of a histidine tag, a myc tag
and a myc-his tag.
18. An isolated carboxypeptidease enzyme, CPG2, in which an
immunogenic region is modified to reduce immunogenicity to a
mammalian immune system whilst retaining CPG2 activity, wherein the
immunogenic region is selected from the group consisting of: (i)
KIDGRGGK (SEQ ID NO.1) comprising residues 98-105 of SEQ ID NO.7;
(ii) KEYGVRD (SEQ ID NO.2) comprising residues 157-163 of SEQ ID
NO.7; (iii) YGVRD (SEQ ID NO.6) comprising residues 159-163 of SEQ
ID NO. 7; (iv) KLADY (SEQ ID NO.3) comprising residues 191-195 of
SEQ ID NO.7; (v) GAGK (SEQ ID NO.4) comprising residues 412 to the
C-terminal residue 415 of SEQ ID NO.7; (vi) AG comprising residues
413-414 of SEQ ID NO.7; and (vii) EGGKKLVDK (SEQ ID NO.5)
comprising residues 331-339 of SEQ ID NO.7; wherein the C-terminus
of the enzyme comprises an extension selected from the group
consisting of a histidine tag, a myc tag and a myc-his tag.
19. The carboxypeptidase enzyme of claim 16 wherein said enzyme is
fused to an antibody other than an anti-CEA antibody.
20. The carboxypeptidase enzyme of claim 17 wherein said enzyme is
fused to an antibody other than an anti-CEA antibody.
21. The carboxypeptidase enzyme of claim 18 wherein said enzyme is
fused to an antibody other than an anti-CEA antibody.
22. A method of preparing a fusion protein comprising a
carboxypeptidase CPG2 enzyme of claim 17 and an antibody other than
a CEA-antibody, comprising expressing a DNA sequence encoding said
fusion operably linked to a promoter in a Pichia pastoris host
cell, and recovering said fusion protein therefrom.
23. A method of preparing a fusion protein comprising a
carboxypeptidase CPG2 enzyme of claim 18 and an antibody other than
a CEA-antibody, comprising expressing a DNA sequence encoding said
fusion operably linked to a promoter in a Pichia pastoris host
cell, and recovering said fusion protein therefrom.
24. A kit comprising a first component which is a prodrug which can
be converted to a cytotoxic drug by a carboxypeptidase of claim 16
and, as a second component, said carboxypeptidase.
25. A kit comprising a first component which is a prodrug which can
be converted to a cytotoxic drug by a carboxypeptidase of claim 17
and, as a second component, said carboxypeptidase.
26. A kit comprising a first component which is a prodrug which can
be converted to a cytotoxic drug by a carboxypeptidase of claim 18
and, as a second component, said carboxypeptidase.
27. A kit comprising a first component which is a prodrug which can
be converted to a cytotoxic drug by a carboxypeptidase of claim 19
and, as a second component, said carboxypeptidase.
28. A kit comprising a first component which is a prodrug which can
be converted to a cytotoxic drug by a carboxypeptidase of claim 20
and, as a second component, said carboxypeptidase.
29. A kit comprising a first component which is a prodrug which can
be converted to a cytotoxic drug by a carboxypeptidase of claim 21
and, as a second component, said carboxypeptidase.
Description
[0001] This application claims benefit of U.S. Provisional
Application No. 60/216,689, the entire contents of which is hereby
incorporated by reference.
FIELD OF THE INVENTION
[0002] The present invention relates to improvements to the enzyme
carboxypeptidase G2, and the use of this enzyme in therapy,
particularly antibody-directed enzyme prodrug therapy (ADEPT) and
gene-directed enzyme prodrug therapy (GDEPT).
BACKGROUND TO THE INVENTION
[0003] Over the years, many cytotoxic compounds have been
discovered which are of potential use in cancer chemotherapy. For
example, nitrogen mustards form one important family of such
cytotoxic compounds. A problem with the clinical use of cytotoxic
compounds is in achieving sufficient selectivity in the cytotoxic
effect between tumour cells and normal cells. One approach to
address this problem has involved the development of so-called
prodrugs which are derivatives of the cytotoxic drug, often
relatively simple derivatives, whose cytotoxic properties are
considerably reduced compared to those of the parent drugs.
Numerous proposals have been made for the administration of such
prodrugs to patients under regimes whereby the prodrug is only
converted by the action of an enzyme to the cytotoxic drug in the
region of the intended site of action.
[0004] A variety of systems exist for delivery of the enzyme. One
such system is described in WO88/07378, and involves conjugating
the enzyme to an antibody specific for a tumour marker, delivering
the antibody enzyme conjugate to a patient, allowing the conjugate
to localise, and then delivering the prodrug to the patient. This
system is referred to as antibody-directed enzyme prodrug therapy"
(ADEPT).
[0005] Another approach for delivery of the enzyme to the desired
site of action is by the use of a genetic construct, such as a
viral or non-viral vector carrying a gene encoding the
prodrug-converting enzyme, which is delivered to cells at the
desired site of action (Huber et al, Proc. Natl. Acad. Sci. USA
(1991) 88, 8039). A further alternative system is to provide a
ligand, generally a naturally occurring polypeptide whose
biological role involves its binding to a cognate receptor on the
surface of the cell, conjugated to the prodrug-activating enzyme.
This system, LIDEPT, is described in WO/97/26918, where VEGF is
particularly exemplified as an example of a ligand. A further
alternative system is to use bacterial delivery systems, for
example, Clostridium or Salmonella based systems, in which bacteria
selectively colonise tumours. A Clostridium based system is
described in, for example, Fox et al, 1996 Gene Therapy 3
173-178.
[0006] One class of prodrugs suggested for use in the above systems
is that of prodrugs of nitrogen mustard compounds. Benzoic acid
nitrogen mustards are bifunctional alkylating agents, and a variety
of prodrugs of such compounds are described in the art. One class
of such prodrugs comprise a protecting group which may be removed
by the action of a carboxypeptidase enzyme, such as bacterial
carboxypeptidase G, particularly the Pseudomonas-derived enzyme
carboxypeptidase G2 (CPG2). CPG2 is a well characterised enzyme
with no mammalian equivalent. It is a non-covalently associated,
homo-dimeric, metalloenzyme which cleave the C-terminal glutamic
acid of folate to yield a pteroate derivative. This has been
exploited to cleave glutamic acid from a variety of prodrugs to
release potent nitrogen mustard compounds.
[0007] Examples of prodrugs which may be activated by CPG2 are
described in, for example, Springer et al., Anti-Cancer Drug Design
(1991) 6; 467-479, WO88/07378, WO94/25429 and WO96/22277. Fusions
of an antibody fragment directed against carcinoembryonic antigen
(CEA) with CPG2 have been described in Michael et al,
Immunotechnology 2 47-57 (1996) and the use of this fusion in in
vivo model systems has been described in Bhatia et al, Int. J.
Cancer, 85; 571-577 (2000).
[0008] A feature of CPG2 is that being a bacterial enzyme, it does
not occur naturally in the body of a human patient, and thus
prodrugs designed to be activated by this enzyme will not be
activated elsewhere in the patient. However, the drawback to this
feature is that the enzyme provokes an immune response in a
patient, and indeed such responses have been observed in clinical
trials of ADEPT using CPG2 (Sharma et al, 1992, Cell Biophys.,
21;109-120; Bagshawe et al, 1995, Tumour Targeting, 1; 17-30).
DISCLOSURE OF THE INVENTION
[0009] We have investigated the immunogenicity of CPG2 and
identified a number of regions of this enzyme which contain
epitopes which appear to be involved in the production of a host
immune response. We have found that where a host immune response is
caused by the presence of such epitopes, these epitopes may be
modified to alter the immunogenicity in patients. However the
invention is not limited to this aspect alone, since modifications
to these epitopes may be provided which render the CPG2 less
reactive with sera from CPG2 immunised patients. The latter aspect
of the invention is also advantageous, to allow the development of
CPG2 fusions which "escape" or "evade", to a greater or lesser
degree, an immune response of a host which has been provoked by a
wild-type CPG2 or another altered form of CGP2 which has a set of
one or more epitope modifications which cause an established host
response to a previously administered form of CGP2 to be less
effective against the newly altered form.
[0010] Throughout this text where specific amino acids or amino
acid sequences of the Pseudomonas CPG2 used in the examples below
are referred to we have used the numbering used in the Swiss Prot
database entry for CPG2 (accession number p06621). The unprocessed
form of CPG2 has a sequence 415 amino acids long. The first 22
residues of this sequence are removed in the processed form of
CPG2. In the MFE-23::CPG2 fusion protein described here, the first
amino acid of the CPG2 domain is amino acid 25 according to the
Swiss Prot CPG2 entry.
[0011] In a first aspect, the invention provides a CPG2 enzyme in
which an immunogenic region selected from:
[0012] KIKGRGGK (amino acids 98-105, SEQ ID NO:1)
[0013] KEYGVRD (157-163, SEQ ID NO:2), preferably YGVRD
(159-163)
[0014] KLADY (191-195, SEQ ID NO:3)
[0015] GAGK (412-C-terminal(415), SEQ ID NO:4), preferably AG
(413-414),
[0016] EGGKKLVDK (331-338, SEQ ID NO:5)
[0017] is modified to reduce or alter immunogenicity to a mammalian
immune system whilst retaining CPG2 activity.
[0018] In another aspect, we have also found that production of
fusions of CPG2 with an antibody, where the CPG2 protein has been
tagged provides a CPG2 protein which has reduced immunogenicity.
Thus in a further aspect of the invention, there is provided a CPG2
enzyme, including any of those of the first aspect, which is tagged
with a his or myc-his tag.
[0019] There is also provided by the invention methods of treatment
or diagnosis by methods such as ADEPT, GDEPT or LIDEPT which
utilise the CPG2 of the present invention. These and other aspects
of the invention are described herein in more detail below.
DESCRIPTION OF THE DRAWINGS
[0020] FIG. 1 illustrates inhibition of CPG2 binding of human
antibodies by CM79 determined by ELISA. Sera A1 to A10 were from
ten patients post treatment with an A5B7-CPG2 antibody-enzyme
conjugate used in an ADEPT clinical trial. Values are
mean.+-.SEM.
[0021] FIG. 2 illustrates three segments of the SELDI epitope
mapping mass spectra of CPG2 with CM79 (left hand spectra) and with
non-CPG2 binding sFv M009 controls (right hand spectra).
[0022] 2A) Glu-C digested CPG2 peptides R[356-415]K (mass 6269.8
Da) and S[376-415]K (mass 4354.1 Da).
[0023] 2B) Glu-C digested CPG2 peptides Y[391-415]K (mass 2794.9)
and Y[159-189]E (mass 3539.9 Da).
[0024] 2C) Glu-C digested CPG2 peptides Y[159-176]E (mass 2092.8
Da)
[0025] FIG. 3A shows a representation of the X-ray crystal derived
structure of CPG2, showing regions I and II.
[0026] FIG. 3B shows the amino acid sequence of CPG2.
[0027] FIG. 4 illustrates CM 79 binding to wt CPG2, variant V6 and
variant V8, determined by ELISA.
[0028] FIG. 5 illustrates an example of patient serum (A21) binding
to wt CPG2 and variant V6. Binding was determined by ELISA. (Serum
dilution 0.1=a 1 in 10 fold dilution.
[0029] FIG. 6 illustrates plasma clearance of CPG2 activity in
LS174T xenografted nude mice given MFE23::CPG-gly-his fusion
protein.
[0030] FIG. 7 illustrates biodistribution of CPG2 activity in
LS174T xenografted nude mice given MFE23::CPG-gly-his fusion
protein.
[0031] FIG. 8 illustrates tumour to normal tissue ratios in LS174T
xenografted nude mice given MFE23::CPG-gly-his fusion protein.
[0032] FIG. 9A illustrates time-activity curves for actual tumour
and blood data for the glycosylated fusion protein along with the
models that describe blood clearance and uptake of the non-specific
(NS) antibody in tumour.
[0033] FIG. 9B illustrates time-activity curves for actual tumour
and blood data for the non-glycosylated fusion protein along with
the models that describe blood clearance and uptake of the
non-specific (NS) antibody in tumour.
[0034] FIG 10A illustrates the effect of ADEPT therapy in LS174T
xenografted nude mice given MFE23::CPG-gly-myc-his fusion protein
in combination with bis-iodo phenol mustard prodrug (ZD2767P).
[0035] FIG 10B illustrates the effect of ADEPT therapy in LS174T
xenografted nude mice given MFE23::CPG-gly-his fusion protein in
combination with bis-iodo phenol mustard prodrug (ZD2767P).
[0036] FIG. 11A illustrates toxicity measured as weight loss in
LS174T xenografted nude mice given MFE23::CPG-gly-myc-his fusion
protein in combination with bis-iodo prodrug.
[0037] FIG. 11B illustrates toxicity measured as weight loss in
LS174T xenografted nude mice given MFE23::CPG-gly-his fusion
protein in combination with bis-iodo prodrug.
[0038] FIG. 12 illustrates the CPG2 molecule showing the molecular
dynamics predicted interaction of a charged histidine residue in
the hexa-His-tag with a residue from the epitope KEYGVRD, residues
157-163.
[0039] FIG. 13 illustrates the CPG2 molecule (chain A only) showing
the molecular dynamics predicted interaction of an uncharged
histidine residue in the hexa-His-tag with a residue from the
epitope EGGKKLVDK, residues 331-339, the prediction assuming an
uncharged His-tag.
[0040] FIG. 14 illustrates the CPG2 molecule (chain A only) showing
the molecular dynamics predicted interaction of a glutamate residue
in the Myc tag with a residue from the epitope EGGKKLVDK, residues
331-339.
DETAILED DESCRIPTION OF THE INVENTION
[0041] The modifications to the immunogenic regions identified
above may be any type of modifications which have the defined
function of retaining CPG2 activity and being reduced or altered in
immunogenicity. These are essentially functional tests which those
of skill in the art can perform using routine skill and
knowledge.
[0042] Thus for example, CPG2 activity may be tested by the ability
of the enzyme to hydrolyse methotrexate (MTX). CPG2 hydrolysis of
MTX results in a change in absorbance at 320 nm which may be
measured by spectrophotometry. CPG2 catalytic activity in solid
tissues can be assayed using an indirect HPLC method, measuring,
for example, 2,4-diamino-N.sup.10 methypteroic acid (DAMPA, a
metabolite of MTX). Examples of further tests are described in
McCulloch et al, J. Biol. Chem. 246:7207-7213, 1971 and Sherwood et
al, Eur. J. Biochem. 148: 447-453, 1985.
[0043] The reduction or alteration in immunogenicity of the
modified enzyme may be determined by injecting the enzyme into a
test animal, typically a mouse, and assaying the immune response of
the mouse to one or more--e.g. 2, 3, 4 or 5 repeat injections of
the modified enzyme compared to an unmodified control. Such a
protocol is exemplified in the accompanying examples, and may be
used in similar form.
[0044] Particular modifications include:
[0045] substitutions
[0046] deletions
[0047] insertions
[0048] replacement of the immunogenic regions by human sequences of
sequence in particular at positions where intramolecular
interactions are observed to be present in the X ray structure.
[0049] These replacements may be made to retain the correct
stereochemistry, hydrophobicity or charge characteristics, even
where sequence similarity may be low.
[0050] Examples of substitutions include the replacement of charged
residues for uncharged residues, uncharged residues for charged
residues, polar residues for non-polar residues, non-polar residues
for polar residues, large side chain residues for smaller side
chain residues, small side chain residues for larger side chain
residues. Specific residues that may be substituted include R162
and G412. Other CPG2 amino acids to be substituted will be
identified using anti-CPG2 antibodies/antibody fragments
particularly where these can block human anti-CPG2 antibodies as
identified using enzyme linked immunosorbent assay (ELISA). These
anti-CPG2 antibodies will be epitope mapped. Subsequent
substitution of amino acids in these CPG2 epitopes will be of those
type mentioned.
[0051] The MFE-23::CPG2-his fusion protein has a hexa-His tag at
the C-terminus of CPG2. This tag may be extended by inserting
sequences of varying length between the hexa-His tag and the
C-terminus of CPG2. Insertions include the myc tag (EQKLISEEDLN) to
result in a myc-his tag having the sequence
AAASFLEQKLISEEDLNSAVDHHHHHH, or a humanized version of the myc tag.
Such insertions may serve to mask immunogenic surfaces on the CPG2
protein.
[0052] Usually, no more than 10, for example from 5 to 10, such as
5, preferably no more than 4, for example 3, 2 or just one
substitution will be made to the native CPG2 sequence in each of
the immunogenic regions identified. The enzyme may comprise 1, 2,
3, 4 or from 5 to 10 substituted immunogenic regions.
[0053] Similarly, no more than 10, for example from 5 to 10, such
as 5, preferably no more than 4, for example 3, 2 or just one
deletion will be made to the native CPG2 sequence in each of the
immunogenic regions identified. The enzyme may comprise 1, 2, 3, 4
or from 5 to 10 immunogenic regions carrying a deletion.
[0054] Likewise, no more than 10, for example from 5 to 10, such as
5, preferably no more than 4, for example 3, 2 or just one
insertion will be made to the native CPG2 sequence in each of the
immunogenic regions identified. The enzyme may comprise 1, 2, 3, 4
or from 5 to 10 immunogenic regions in which an insertion has been
made. Examples of insertions include the replacement of surface
loops, extensions of either the C-terminus or the N-terminus or the
replacement of any segmented sequence where the exposed residues
may be substituted for other residues but where the buried residues
are conserved so as to minimise disruption of the 3-D
structure.
[0055] In the case of the C-terminal immunogenic region, the
modification may be by way of an extension to the C-terminus of the
enzyme. We have surprisingly found that addition of a polyhistidine
tag to the C-terminus of CPG2 provided a significant reduction in
immunogenicity. The further addition of a myc tag to the
polyhistidine tag provided a further decrease.
[0056] The histidine tag is a synthetic tag widely used in the art
to aid protein purification or identification. It is not a native
human or murine epitope and it is therefore surprising that its
addition is beneficial in reducing the immune response. The myc tag
is derived from the c-myc proto-oncogene and would normally not be
expected to provoke a response in its native conformation in
humans.
[0057] C-terminal extensions may thus be selected broadly, although
in general terms such extensions will typically be short peptide
sequences of, for example, from 5 to 20 amino acids, and may be
synthetic sequences or natural sequences of mammalian, particularly
human origin. Two or more, such as from 2 to 5 such sequences
(which may be the same or different) may be added in tandem.
[0058] Replacement of these immunogenic regions may be by human
sequences of similar sequence to the wild type sequence, or by
sequences exhibiting similar conformations, or by sequences
exhibiting similar hydrophobic, charge, stereochemical or surface
exposure characteristics. In an example procedure, the sequence,
conformation and interior protein contact profile of an immunogenic
region would be encoded as a set of criteria on which to search and
select similar regions from a database of human protein
three-dimensional structures (for example, the protein databank
(PDB) could be searched using the IDITIS software (Oxford Molecular
plc, UK)). Such selected regions would then be ranked on their
similarity to the above criteria and the most similar sequence or
sequences used for replacement of an existing immunogenic region.
Where the humanised sequences comprise the same or similar residues
involved in internal packing interactions as the wild type
sequence, the humanised sequence may not require further
modification. If, however, these residues result in structural
perturbations of the internal interactions with the rest of the
molecule, these buried residues may be substituted with residues
present in the wild-type molecule, producing a hybrid sequence
which retains internal packing interactions and stereochemistry.
Examples of suitable regions found using this method for
replacement of the KEYGVRD sequence (SEQ ID NO:2) include the
hybrid sequence (maintaining intramolecular contacts) YEYGVMK of
the humanised sequence YEVGMMK. Examples of suitable sequences for
replacement of KLADY (SEQ ID NO:3) include the hybrid sequence
(maintaining intramolecular contacts) RNSDY of the humanised
sequence RNSDR.
[0059] In a related aspect of the invention, we have found that
expression of MFECPG2 in Pichia pastoris provides advantages over
bacterially produced CPG2. The enzyme CPG2 is bacterial and thus in
its native form is not glycosylated. However, the sequence of the
enzyme contains three motifs Asn-Xaa-Thr/Ser which are recognised
by eukaryotic cells as targets for N-linked glycosylation, (1), (2)
and (3). These three Asn residues which are glycosylated are found
at positions 222, 264 and 272 of Pseudomonas CPG2. As mentioned
above, CPG2 is a homo-dimer and it has been found that N-linked
glycosylation appears to interfere with the formation of the dimer,
particularly at its second position, 264.
[0060] Surprisingly, we have found that production of the enzyme in
P. pastoris results in glycosylation only at residues 222 and 272,
thus reducing the interference caused by glycosylation at 264 which
occurs in CPG2 produced in, for example, mammalian cells.
[0061] We have also found that by using partially glycosylated
enzyme obtainable by P. pastoris expression, the efficacy of
antibody-CPG2 fusions is enhanced, in that the enzyme localises to
the tumour whilst being cleared efficiently from other organs and
the bloodstream of the mammalian body.
[0062] Thus the invention provides a CPG2 enzyme which is partially
N-linked glycosylated at one or both of positions (1) and (3), and
not N-linked glycosylated at position (2). Preferably, position (2)
retains its native sequence and is not glycosylated as a result of
expression in P. pastoris.
[0063] Expression of the CPG2 wherein the motifs (1), (2) and (3)
are all present is preferably in a P. pastoris host cell, or a host
cell of a yeast, such as a methylotrophic yeast. Such yeasts are
those which are capable of growth on methanol and include yeast of
the genera Hansenula, Candida, Kloeckera, Pichia, Saccharomyces,
Torulopsis and Rhodotorula. A list of specific species which are
exemplary of this class of yeasts may be found in C. Anthony, The
Biochemistry of Methylotrophs, 269 (1992). Pichia, particularly
P.pastoris, is preferred.
[0064] In the present invention, a preferred CPG2 enzyme which is
used is the CPG2 whose sequence is disclosed in WO88/07378 and
herein in FIG. 3B, the disclosure of which is incorporated herein
by reference. However, other bacterial carboxypeptidase enzymes may
be used, e.g., CPG2 enzymes from Variovorax species such as
Variovorax paradoxes and CPG2 enzymes from other Pseudomonas
species such as Pseudomonas aeruginosa, Pseudomonas cepacia,
Pseudomonas fluorescens, Pseudomonas putida, Pseudomonas syringae,
Pseudomonas savastanoi, which in the native form comprise three
asparagine residues, Asn (1), Asn (2), Asn (3) numbered in the
N-terminal to C-terminal direction, the residues being part of
motifs which on expression in a mammalian cell are subject to
N-linked glycosylation. In such enzymes Asn (1), Asn (2) and Asn(3)
will be at positions homologous to Asn 222, Asn 264 and Asn 272,
although they may have different positional numbering. However, Asn
(1), Asn (2) and Asn (3) of these enzymes can readily be identified
by persons skilled in the art, for example using sequence
alignments to compare a sequence with the sequence shown herein,
and thereby identify the Asn residues which correspond to Asn 222,
Asn 264 and Asn 272 of FIG. 3B. Likewise, the epitopes identified
as SEQ ID NOS: 1 to 5 above may have different positional numbering
and/or minor modifications to the wild type sequence but can be
determined by those skilled in the art by the modelling techniques
described herein by analogy to FIG. 3B. CPG2 enzymes from other
species of Pseudomonas may be obtained by routine cloning
methodology. For example, a library of CDNA from a Pseudomonas
species may be made and probed with all or a portion of the
sequence of FIG. 3B under conditions of medium to high
stringency.
[0065] For example, hybridizations may be performed, according to
the method of Sambrook et al. (below) using a hybridization
solution comprising: 5.times.SSC (wherein `SSC`=0.15 M sodium
chloride; 0.15 M sodium citrate; pH 7), 5.times. Denhardt's
reagent, 0.5-1.0% SDS, 100 .mu.g/ml denatured, fragmented salmon
sperm DNA, 0.05% sodium pyrophosphate and up to 50% formamide.
Hybridization is carried out at 37-42 C for at least six hours.
Following hybridization, filters are washed as follows: (1) 5
minutes at room temperature in 2.times.SSC and 1% SDS; (2) 15
minutes at room temperature in 2.times.SSC and 0.1% SDS; (3) 30
minutes-1 hour at 37 C in 1.times.SSC and 1% SDS; (4) 2 hours at
42-65 C in 1.times.SSC and 1% SDS, changing the solution every 30
minutes.
[0066] Clones identified as positive may be examined to identify
open reading frames encoding homologues of the sequence shown in
FIG. 3B. It may be necessary to combine more than one clone to
achieve a full length open reading frame, as would be understood by
the person skilled in art. Clones may then be expressed in a
heterologous expression system, e.g. in bacteria or yeast and the
protein purified by techniques known in the art.
[0067] Alternatively, CPG2 enzyme producing bacteria may be
identified by methods involving the identification of organisms
that convert folic acid to pteroate or of organisms capable of
growing on media with folic acid as the sole carbon source.
[0068] Suitable enzymes to which mutations according to the
invention may be applied include carboxypeptidase enzymes which are
mutants, variants, derivatives or alleles of the sequence shown in
FIG. 3B. A carboxypeptidase enzyme which is a variant, allele,
derivative or mutant may have an amino acid sequence which differs
from that given in FIG. 3B by one or more of addition,
substitution, deletion and insertion of one or more amino acids,
for example from 1 to 20, such as from 1 to 10, e.g., 1,2,3,4,5 or
6-10 substitutions deletions or insertions.
[0069] Preferred such carboxypeptidases will have the ability to
hydrolyse methotrexate (MTX). Alteration of sequence may change the
nature and/or level of activity and/or stability of the
carboxypeptidase enzyme.
[0070] A polypeptide which is an amino acid sequence variant,
allele, derivative or mutant of the amino acid sequence shown in
FIG. 3B may comprise an amino acid sequence which shares greater
than about 35% sequence identity with the sequence shown, greater
than about 40%, greater than about 50%, greater than about 60%,
greater than about 70%, greater than about 80%, greater than about
90% or greater than about 95%. The sequence may share greater than
about 60% similarity, greater than about 70% similarity, greater
than about 80% similarity or greater than about 90% similarity with
the amino acid sequence shown in FIG. 3B. Amino acid similarity is
generally defined with reference to the algorithm GAP (Genetics
Computer Group, Madison, Wis.) as noted above, or the TBLASTN
program, of Altschul et al. (1990) J. Mol. Biol. 215: 403-10.
Parameters employed are the default ones: for nucleotide
sequences--Gap Weight 50, Length Weight 3, Average Match 10.000,
Average Mismatch 0.000; for peptide sequences--Gap Weight 8, Length
Weight 2, Average Match 2.912, Average Mismatch -2.003. Peptide
similarity scores are taken from the BLOSUM62 matrix. Also useful
is the TBLASTN program, of Altschul et al. (1990) J. Mol. Biol.
215: 403-10, or BestFit, which is part of the Wisconsin Package,
Version 8, September 1994, (Genetics Computer Group, 575 Science
Drive, Madison, Wis., USA, Wisconsin 53711). Sequence comparisons
may be made using FASTA and FASTP (see Pearson & Lipman, 1988.
Methods in Enzymology 183: 63-98). Parameters are preferably set,
using the default matrix, as follows: Gapopen (penalty for the
first residue in a gap): -12 for proteins/-16 for DNA; Gapext
(penalty for additional residues in a gap): -2 for proteins/-4 for
DNA; KTUP word length: 2 for proteins/6 for DNA.
[0071] Sequence comparison may be made over the full-length of the
relevant sequence shown herein, or may more preferably be over a
contiguous sequence of about or greater than about 20, 25, 30, 33,
40, 50, 67, 133, 167, 200, 233, 267, 300, 333, or more amino acids
or nucleotide triplets, compared with the relevant amino acid
sequence or nucleotide sequence as the case may be.
[0072] In further aspects the invention provides a nucleic acid
encoding such modified bacterial carboxypeptidases or vectors
comprising such nucleic acid. The vector is preferably an
expression vector, wherein said nucleic acid is operably linked to
a promoter compatible with a host cell. The invention thus also
provides a host cell which contains an expression vector of the
invention.
[0073] Host cells of the invention may be used in a method of
making a carboxypeptidase enzyme of the invention as defined above
which comprises culturing the host cell under conditions in which
said enzyme or fragment thereof is expressed, and recovering the
enzyme in substantially isolated form. The enzyme may be expressed
as a fusion protein.
[0074] Host cells may be used to provide fusions of antibody-enzyme
conjugates for use in ADEPT therapy, for ligand-enzyme conjugates
for LIDEPT therapy, or may be used in the provision of vectors such
as viral vectors for GDEPT therapies. ADEPT therapy has utility in
the treatment of tumours which are associated with tumour specific
markers, which may be the target for an antibody. By "antibody",
this is intended to refer to any binding fragment thereof,
characterised by the presence of a VH, and preferably also a VL
region. Such fragments include single chain Fv and Fab
fragments.
[0075] Examples of tumour antigens include CEA, a cell surface
glycoprotein strongly expressed by most colorectal tumours.
Colorectal cancer is the second leading cause of cancer death in
the UK. Conventional treatments remain unable to cure patients with
advanced or metastatic disease. CEA is a suitable target for ADEPT
because, with highly specific antibodies, CEA is only detectable on
tumours and on the luminal surface of the gut which is not readily
accessible to IgG antibodies. A particular anti-CEA antibody is
MFE-23 which is disclosed in WO95/15341. Other antibody chemical
conjugates with CPG2 which have been proposed for ADEPT therapy are
the anti-human chorionic gonadotropin monoclonal antibody (MAb) W14
F(ab')2 and the anti-c-erbB2 MAb ICR12 (Bagshawe, 1998, Tumor
targeting, 3: 21-24, 1998) and the CPG2 of the present invention
may be used in such conjugates.
[0076] More generally however, for ADEPT it is not essential that
the target antigen is attached to the cell surface, as prodrug can
be converted to active drug in the tumour interstitial space and
diffuse into the tumour cells. Targets that are secreted or cleaved
from tumour cells, or produced in tumour stroma, may be applicable.
A target which is heterogeneously expressed, as often occurs with
tumour antigens, is similarly acceptable.
[0077] Thus other targets which exist include for example the
idiotype in lymphomas or mutant cell-surface proteins, which are
increasingly being identified, in other tumours [Urban JL and
Schreiber H, (1992) Tumour antigens. Ann Rev Immunol 10, 617-644.]
relative abundance may give adequate selectivity for ADEPT although
the normal tissue reactivity should be well defined. In some cases
the forms expressed in normal tissue may be relatively inaccessible
to antibody, as for example with CEA discussed above.
[0078] Another target which has been investigated is p185.sup.HER2
which is upregulated in breast cancer. This antigen is also
expressed on a variety of normal epithelial cells but in vitro
experiments have shown that the relative abundance of p185.sup.HER2
on a breast tumour cell line was sufficient to allow specific
targeting in ADEPT [Rodrigues M L, et al, (1995) Cancer Res. 55,
63-70]. Where antigens are expressed in normal tissues their
pattern of distribution should be considered when choosing a
suitable toxic agent. For example, the enzyme .beta.-lactamase,
genetically fused to anti-p185.sup.HER2, has been used to generate
the drug doxorubicin for which heart tissue is a site of chronic
and dose limiting toxicity and bone marrow is a site of acute
toxicity. As there is no detectable expression of p185.sup.HER2 in
heart or bone marrow the above ADEPT combination seems particularly
suitable for this antigen.
[0079] Tumour vasculature is an attractive target for some antibody
therapies as it is readily accessible and essential for tumour
growth. Moreover, experimental models have demonstrated the
potential efficacy of targeted immunotoxins to kill tumour
endothelial cells [Burrows F J and Thorpe P E, (1993) Proc Natl
Acad Sci USA 90, 8996-9000]. Tumour vasculature may provide a good
target for ADEPT if the prodrug is designed to have a very short
half life so that active drug does not leak back into normal
tissues via the blood.
[0080] Suitable viral vectors for VDEPT include those which are
based upon a retrovirus. For GDEPT, a wide variety of vectors are
available. These include those which are based upon a retrovirus.
Such vectors are widely available in the art. Huber et al (ibid)
report the use of amphotropic retroviruses for the transformation
of hepatoma, breast, colon or skin cells. Culver et al (Science
(1992) 256; 1550-1552) also describe the use of retroviral vectors
in GDEPT. Such vectors or vectors derived from such vectors may
also be used. Other retroviruses may also be used to make vectors
suitable for use in the present invention. Such retroviruses
include rous sarcoma virus (RSV). The promoters from such viruses
may be used in vectors in a manner analogous to that described
above for MLV.
[0081] EP-A-415 731 describes molecular chimeras comprising a
promoter which may be activated in a tumour cell operably linked to
a heterologous gene encoding an enzyme capable of converting a
prodrug into a cytotoxic agent. Such molecular chimeras may be used
to express enzymes of the invention in tumour cells in order to
activate prodrugs. EP-A-415 731 describes incorporation of such
molecular chimeras into viral vectors, e.g. adenoviral or
retroviral vectors. Such viral vectors may also be adapted for
utilization in the present invention.
[0082] Other recombinant viral vector delivery systems are
described in WO91/02805, WO92/14829, WO93/10814, WO94/21792,
WO95/07994, WO95/14091 and WO96/22277, the disclosures of which are
incorporated herein by reference. Methods for producing vector
delivery systems based on the above-mentioned disclosures may be
used to deliver vectors encoding the activating enzyme to target
cells.
[0083] Englehardt et al (Nature Genetics (1993) 4; 27-34) describes
the use of adenovirus based vectors in the delivery of the cystic
fibrosis transmembrane conductance product (CFTR) into cells, and
such adenovirus based vectors may also be used in accordance with
the present invention. Vectors utilising adenovirus promoter and
other control sequences may be of use in delivering a system
according to the invention to cells in the lung, and hence useful
in treating lung tumours.
[0084] Vectors encoding the CPG2 carboxypeptidase may be made using
recombinant DNA techniques known per se in the art. The sequences
encoding the enzyme may be constructed by splicing synthetic or
recombinant nucleic acid sequences together, or modifying existing
sequences by techniques such as site directed mutagenesis.
Reference may be made to "Molecular Cloning" by Sambrook et al
(1989, Cold Spring Harbor) for discussion of standard recombinant
DNA techniques. In general, the vector may be any DNA or RNA vector
used in GDEPT therapies.
[0085] The CPG2 carboxypeptidase will be expressed from the vector
using a promoter capable of being expressed in the cell to which
the vector is targeted. The promoter will be operably linked to the
sequences encoding the enzyme and its associated sequences.
[0086] Suitable promoters include viral promoters such as mammalian
retrovirus or DNA virus promoters, e.g. MLV, CMV, RSV and
adenovirus promoters. Preferred adenovirus promoters are the
adenovirus early gene promoters. Strong mammalian promoters may
also be suitable. An example of such a promoter is the EF-1.alpha.
promoter which may be obtained by reference to Mizushima and Nagata
((1990), Nucl. Acids Res. 18; 5322). Variants of such promoters
retaining substantially similar transcriptional activities may also
be used.
[0087] The c-erbB2 proto-oncogene is expressed in breast tissues at
low levels and in a tissue restricted manner. In some tumour
states, however, the expression of this protein in increased, due
to enhanced transcriptional activity. Notable examples of this are
breast tissue (about 30% of tumours), ovarian (about 20%) and
pancreatic tumours (about 50-75%). In such tumours where expression
of c-erbB2 is increased due to enhanced transcription or
translation, the c-erbB2 promoter may be used to direct expression
of the activating enzyme in a cell specific manner. The specificity
of GDEPT may be increased since transfection of normal cells by a
vector with a c-erbB2 promoter will provide only very limited
amount of enzyme or none and thus limited activation of prodrug.
The use of the c-erbB2 promoter and homologous promoters in GDEPT
is more fully described in WO96/03151.
[0088] The prodrug for use in the system will be selected to be
compatible with the CPG2 carboxypeptidase such that the enzyme will
be capable of converting the prodrug to the active drug. Desirably,
the toxicity of the prodrug to the patient being treated will be at
least one order of magnitude less toxic to the patient than the
active drug. Preferably the active drug will be several, e.g. 2, 3
or 4 or more orders of magnitude more toxic than the prodrug.
Nitrogen mustard prodrugs are preferred. Other suitable prodrugs
include those disclosed in WO96/03515.
[0089] Nitrogen mustard prodrugs include compounds of the
formula:
M-Ar--CONH--R
[0090] where Ar represents an optionally substituted aromatic ring
system, R--NH is the residue of an .alpha.-amino acid R--NH.sub.2
or oligopeptide R--NH.sub.2 and contains at lease one carboxylic
acid group, and M represents a nitrogen mustard group. The residue
of the amino acid R--NH is preferably the residue of glutamic acid.
It is disclosed in WO88/07378 that the enzyme carboxypeptidase G2
is capable of removing the glutamic acid moiety from compounds of
the type shown above, and the removal of the glutamic acid moiety
results in the production of an active nitrogen mustard drug.
Prodrugs of a similar structure are also disclosed in WO94/02450,
the disclosure of which is incorporated herein by reference.
[0091] In a further aspect, the present invention provides a
pharmaceutical composition, medicament, drug or other composition
comprising an enzyme of the invention. The composition may include
a pharmaceutically acceptable carrier or diluent.
[0092] The invention also provides a kit comprising:
[0093] (a) a prodrug which can be converted to a cytotoxic drug by
CPG2; and one of
[0094] (b(i)) an immunoglobulin/enzyme fusion protein or conjugate
in which the immunoglobulin is specific for a cellular (e.g.
tumour-associated) antigen and the enzyme is a carboxypeptidase
enzyme;
[0095] (b(ii)) a ligand-enzyme conjugate or fusion protein, the
ligand being specific for a cellular (e.g. tumour associated
antigen) and the enzyme is a carboxypeptidase enzyme;
[0096] (b(iii)) a vector which encodes a carboxypeptidase enzyme
which can be expressed in a cell (e.g. tumour cell)
[0097] the carboxypeptidase being a carboxypeptidase of the
invention.
[0098] In the kits of the invention, the vectors conjugates or
fusion proteins may themselves be provided in a composition
including a pharmaceutically acceptable carrier or diluent.
[0099] Compositions according to the present invention, and for use
in accordance with the present invention, may include, in addition
to active ingredient, a pharmaceutically acceptable excipient,
carrier, buffer, stabiliser or other materials well known to those
skilled in the art. Such materials should be non-toxic and should
not interfere with the efficacy of the active ingredient. The
precise mature of the carrier or other material will depend on the
route of administration, which may be oral, or by injection, e.g.
cutaneous, subcutaneous or intravenous.
[0100] Administration of the prodrug and/or vector and/or fusion
and/or conjugate is preferably in a "therapeutically effective
amount", that being sufficient to show benefit to the patient. The
doses of each component and the route and time-course of their
administration will ultimately be at the discretion of the
physician, who will take into account such factors as the nature
and severity of what is being treated and the age, weight and
condition of the patient.
[0101] Suitable doses of prodrug and conjugate for the ADEPT
approach are given in Bagshawe et al. Antibody, Immunoconjugates,
and Radiopharmaceuticals (1991), 4, 915-922. A suitable dose of
conjugate may be from 2000 to 200,000 enzyme units/m.sup.2 (e.g.
20,000 enzyme units/m.sup.2) and a suitable dose of prodrug may be
from 20 to 2000 mg/m.sup.2 (e.g. 200 mg/m.sup.2).
[0102] In order to secure maximum concentration of the fusion
protein or conjugate at the site of desired treatment, it is
normally desirable to space apart administration of the two
components by at least 4 hours. The exact regime will be influenced
by various factors including the nature of the tumour to be
targeted and the exact nature of the prodrug. A typical regime is
to administer the conjugate at 0 h, galactosylated clearing
antibody at 24 h, and prodrug at 48 h. If no clearing antibody is
used, it would generally be longer than 48 h before the prodrug
could be injected.
[0103] In using the LIDEPT systems of the present invention the
prodrug will usually be administered following administration of
the ligand-enzyme fusion protein or conjugate. Typically, the
ligand/enzyme will be administered to the patient, and its uptake
monitored, for example by recovery and analysis of a biopsy sample
of targeted tissue or by injecting trace-labelled protein ligand
enzyme.
[0104] In using the GDEPT system the prodrug may be administered
following administration of the vector encoding the activating
enzyme. Typically, the vector will be administered to the patient
and then the uptake of the vector by transfected or infected (in
the case of viral vectors) cells monitored, for example by recovery
and analysis of a biopsy sample of targeted tissue.
[0105] The amount of vector delivered will be such as to provide an
effective cellular concentration of enzyme so that the prodrug may
be activated in sufficient concentration at the site of a tumour to
achieve a therapeutic effect, e.g. reduction in the tumour size.
This may be determined by clinical trials which involve
administering a range of trial doses to a patient and measuring the
degree of infection or transfection of a target cell or tumour. The
amount of prodrug required will be similar to or greater than that
for ADEPT systems of the type mentioned above.
[0106] A treatment according to the present invention may be
administered alone or in combination with other treatments, either
simultaneously or sequentially dependent upon the condition to be
treated.
[0107] In one aspect, the finding of immunogenic "hot-spots"
provides a novel therapeutic method wherein a patient is
administered different forms of CPG2 of the invention in successive
rounds of therapy, such that any antibody response to a first
modified CPG2 of the invention is not provoked by a second,
different CPG2 of the invention which is administered in a second
(or subsequent) round of therapy. Furthermore, a patient may be
administered a wild-type form of CPG2 of the invention in a first
round of therapy, followed after the first round (which may be more
than one dose of wild-type CPG2) with a CPG2 of the present
invention.
EXAMPLES OF THE INVENTION
Example 1
Identification and Modification of Immunogenic Epitopes
[0108] As described below, from a filamentous phage library of
antibody genes obtained from CPG2 immunized mice we isolated two
single chain Fv antibody fragments (CM79 and CM12) that partially
blocked the polyclonal antibody response generated in patients who
received CPG2 in ADEPT therapy. Using specialized metal chips
coated with CM79/CM12 followed by antigen binding, selective
proteolysis and surface enhanced laser desorption ionization
affinity mass spectrometry (SELDI-AMS) the immunogenic region of
CPG2 was characterised as incorporating the C-terminus and three
loops from sequentially remote sequences which bound to both CM79
(C-terminus and one loop) and CM12 (three loops). (From these
results, the immunogenic regions corresponding to SEQ ID NOS:
1,2,3,4 were derived. We confirmed and silenced the epitopes
corresponding to SEQ ID NO:2 and SEQ ID NO:4 by mutagenesis to give
CPG2 variants with negligible binding to CM79. The variants showed
significant reduction in reactivity against sera from patients with
post-therapy immune responses to wild-type CPG2.
[0109] 1.1 Characterization of the Anti-CPG2 Antibody Phage
Library.
[0110] An anti-CPG2 antibody library was generated containing
1.78.times.10.sup.7 sFv clones. The twelve sFv clones which gave
the highest optical density (OD) readings in ELISA with CPG-coated
plates were chosen. These were then tested by serum inhibition
ELISA for their ability to block the human polyclonal antibody
response made by 2 patients who had received wild-type CPG2 in
ADEPT clinical trials. Results showed a range of 0%-20% inhibition
of patients' sera binding by the sFvs. The strongest inhibitors,
clones CM79 and CM12, were sub-cloned and purified to allow
detailed analysis. CM79-saturated CPG2 was presented to sera from
10 CPG2-immunized patients and reductions of up to 18% of the IgG
response were observed (FIG. 1). Although the examples below
describe in detail the procedures related to CM79 used to identify
epitopes SEQ ID NO:2 and SEQ ID NO:4, it should be understood that
similar procedures were carried out starting with clone CM12
resulting in identification of epitopes SEQ ID NO:1 and SEQ ID
NO:3. The epitope corresponding to SEQ ID NO:5 was identified by
molecular dynamics modelling as described below.
[0111] 1.2 Epitope Identification
[0112] Epitopes were identified using SELDI-AMS epitope mapping and
prediction of surface exposed regions.
[0113] i) SELDI-AMS
[0114] CM79 was subcloned into a pUC119 hexahistidine-tag vector,
expressed and IMAC purified (Casey, J. L. et al. J. Immunol.
Methods 179, 105-116 (1995)). CM79 mass was determined using
SELDI-AMS. To an NP1 SELDI chip (Ciphergen Biosystems Plc, Ca.,
USA) 1 ml of CM79 (0.5 mg/ml in distilled water) was added with
sinapinic acid matrix (5 mg/ml in 50% acetonitrile, 0.5%
trifluoracetic acid). A PBS-1 mass spectrometer (Ciphergen
Biosystems Plc.) was used to collect mass data. The laser intensity
was 20 with 100 shots collected and averaged per sample. For
SELDI-AMS epitope mapping, all incubation stages were 1 h, room
temperature, in a humidity chamber unless stated otherwise. 2 ml of
CM79-His or anti-CEA sFv M009-His (both 0.3 mg/ml), were incubated
on a PS1 SELDI chip (Ciphergen Biosystems Plc.). 4 ml of 1 M
ethanolamine (pH 8) was added to each spot and incubated for 20
min. The chip was washed with 4.times.5 .mu.l of PBS+0.1% Triton
X-100 (PBST) and submerged in PBST for 15 min.
[0115] Antigens (1 ml of 3 mM CPG2+10 mM BSA, or 10 mM BSA) were
incubated on the chip. The chips were washed and incubated with
Glu-C protease (Boehringer-Mannheim-Roche, UK). Enzyme to substrate
ratios were 1:20 or 1:50 diluted in PBST. Protease digestions were
performed for 1.5 h. Matrix was 0.5 .mu.l
.alpha.-cyano-4-hydroxycinnamic acid (CHCA) at 5 mg/ml in 50%
acetonitrile/0.1% trifluoroacetic acid. Mass data was acquired
using the PBS-1 mass spectrometer. 100 samples per spot with laser
intensity setting at 10 were collected and averaged in automatic
mode. Calibration was external using bovine ubiquitin (8564.8
Da).
[0116] ii) Predicting Surface Exposed Regions
[0117] Surface exposed regions of Glu-C digested CPG2 peptides were
determined using the X-ray crystal determined structure of CPG2
(Swiss-Prot. Pdb reference 1CG2), Insight II (MSI, UK) and the DSSP
solvent accessibility algorithm (Rowsell, S. et al. Structure 5,
337-347 (1997)). Glu-C generated fragments of CPG2 were identified
on the Protein Analysis Worksheet (PAWS) (ProteoMetrics, USA).
Analysis of the CPG2 crystal derived conformational structure
(Rowsell, S. et al. Structure 5, 337-347 (1997)) showed that
peptide Y[159-176]E was solvent exposed (Kabsch, W. & Sander,
C. Biopolymers 22, 2577-2637 (1983))(solvent exposure>78%) about
residues Y[159-163]D, which we termed Region I, shown in FIG. 3a.
Peptide Y[391-415]K was solvent exposed about residues 413-414,
this was termed Region II (FIG. 3A). These solvent exposed regions
are only 6 .ANG. apart between Asp163 of Region I and Ala413 of
Region II. The close spatial proximity of the two surface exposed
regions supported their role as the CM79 binding epitope. Molecular
dynamics modelling confirmed these results and moreover suggested
that, with respect to region I (residues 159-163), residues 157 and
158 are also surface exposed and therefore form part of the
epitope. Similarly, molecular dynamics modelling suggested that in
addition to residues 413 and 414 of region II, residues 412 and 415
are also surface exposed and so may form part of the epitope.
Indeed, as described below and as shown in Table 1, substitution of
an alanine residue at residue 412 resulted in decreased CM79
binding. We hypothesized that if Regions I and II comprised a
clinically relevant epitope that we had defined with CM79, then
mutations of that epitope would reduce recognition by CM79 and
patients' antibodies.
[0118] SELDI-AMS combined with Glu-C proteolytic epitope mapping of
the CPG2/CM79 complex identified five CM79 binding peptides derived
from CPG2 (FIG. 2). CPG2 fragments identified were numbered
according to the CPG2 Swiss-Prot entry (accession code P06621)
(FIG. 3b). The observed peptide masses were, 6269.8+H Da assigned
to CPG2 R[356-415]K mass 6270.2 Da (nearest alternative A[314-375]E
mass 6281.1 Da) (FIG. 2A), 4354.1+H Da assigned to CPG2 S[376-415]K
mass 4354.1 Da (nearest alternative A[314-356]E mass 4365.0 Da)
(FIG. 2A), 2794.9+H Da assigned to CPG2 Y[391-415]K mass 2794.4 Da
(nearest alternative A[347-375]E mass 2748.0 Da) (FIG. 2B),
3539.9+H assigned to CPG2 Y[159-189]E mass 3539.8 Da (nearest
alternative K[208-243]E mass 3537.0 Da) (FIG. 2B), and 2092.8+H Da
assigned to CPG2 Y[159-176]E mass 2092.2 Da (nearest alternative
E[355-375]E mass 2063.2 Da) (FIG. 2C). The proteolytic fragments
were all derived from two sequentially remote regions of CPG2.
These results were obtained in duplicate on each assay chip and on
subsequent repetitions of the experiment. Control spectra (right
side of FIG. 2) were performed using non-CPG2 binding sFv M009.
[0119] 1.3 Generation of MFE-23::CPG2-his Variants.
[0120] MFE-23, a recombinant scFv produced by filamentous phage
technology, has shown good localisation to CEA-producing tumours in
patients. MFE-23 is well characterised, is produced in high yields
and has high affinity and specificity for CEA. A radiolabeled
fusion protein of MFE-23::CPG2 expressed in E.coli has been shown
to localise to colorectal tumour xenografts in nude mice(Bhatia et
al, Int. J. Cancer 85 571-577, 2000).
[0121] MFE-23::CPG2 Fusion proteins were produced with variant
CPG2. Changes to (KEYGVRD)(SEQ ID NO:2) were made by insertion of
annealed pairs of oligonucleotides encoding the substituted amino
acids into HindIII and KpnI cohesive termini previously created by
PCR mutagenesis (Purdy, D. et al. J. Medical Microbiol. 49,473-479
(1999)) to flank Region I in wild type (wt) CPG2 plasmid. Changes
to (GAGK)(SEQ ID NO:4) were also prepared. Eight variants are
illustrated in Table 1 and are labelled as V1 to V6.
[0122] CM79 binding and CPG2 enzyme activity of all CPG2 variants
were initially tested in clarified culture supernatants for CM79
binding. The results, shown in Table 1, demonstrate that Arg162 was
critical for CM79 binding (sFv binding to V6 was up to 99% less
than binding to wt MFE-23::CPG2, FIG. 4(wt=wild-type)). The variant
V8 MFE-23::CPG2 indicated the role of the c-terminus in CM79
binding of CPG2 (FIG. 4, Table 1). CM79 bound to all the remaining
CPG2 variants (Table 1).
1TABLE 1 CPG2 variants tested for CM79 binding and enzyme activity.
A single mutation was made in each variant (bold) in either the
KEYGVRD or the GAGK regions. Wild-type MFE-23::CPG2 and variant V6
were CEA affinity chromotography and FPLC purified for CM79
binding, serum binding and enzyme activity assays. epitope
Conformational Region 2 Enzyme Clone Region 1 (C-term.) Activity
CM79 binding wild-type KEYGVRD GAGK Yes Yes CPG2 V1 AEYGVRD GAGK
Yes Yes V2 KAYGVRD GAGK Yes Yes V3 KEAGVRD GAGK Yes Yes V4 KEYAVRD
GAGK Yes Yes V5 KEYGARD GAGK Yes Yes V6 KEYGVAD GAGK Yes Reduced
(up to 99%) V7 KEYGVRA GAGK None Yes V8 KEYGVRD AAGK Yes Reduced
(up to 89%)
[0123] 1.4 ADEPT Patient Sera Binding to Variant V6 and Wild-type
(wt) CPG2
[0124] As variant V6 was shown to have negligible binding to CM79
it was selected for testing for reactivity with patient sera.
[0125] V6 and wild-type (wt) MFE-23::CPG2 were expressed and
purified from 6.times.250 ml culture volumes. Protein yields were
1.3 mg/l for V6 and 0.84 mg/l for wt MFE-23::CPG2. Both proteins
were radiolabelled using the chloramine-T method (Greenwood, F. C.
& Hunter, W. M. Biochem. J. 89, 116-123 (1963)). with 37 MBq
iodine-125 sodium iodide added to 1 ml of 0.5 mg/ml protein.
Radiolabelled proteins were FPLC purified using a Superose 12
column (Pharmacia; PBS mobile phase 0.5 ml/min). Gamma radiation
emitting fractions at 135 kDa elution point were tested for CPG2
enzyme activity. Protein concentrations were determined using Lowry
reagent according to the manufacturer's protocol (BioRad).
[0126] V6 was presented to 15 serum samples from patients who had
antibodies to CPG2 as a result of receiving ADEPT. 2% BSA blocking,
wash and O-phenylenediamine dihydrochloride (Sigma) detection
stages were as described by Bhatia et al(Int. J. Cancer 85 571-577,
2000). ELISA plates (Maxisorb, Nalgene-Nunc International, UK) were
coated overnight at 4.degree. C. with 0.5 mg CPG2, 0.02 mg V6 or
0.02 mg wt MFE-23::CPG2 per well. Library derived sFv binding to
CPG2 was detected with mouse anti-myc tag antibody 9E10, followed
by sheep anti-mouse IgG peroxidase conjugated antibody (SAM-HRP)
(Amersham Life Sciences, UK). To monitor CM79-His binding to CPG2
or the MFE-23::CPG2 variants CM79 was detected using mouse anti-His
tag antibody (Dianova, Germany), followed by SAM-HRP. The patient
serum inhibition assays were performed by saturating CPG2 coated
wells with CM79 at 25 mg/ml. ADEPT patient serum binding to CPG2 or
the MFE-23::CPG2 variants was detected with goat anti-human IgG HRP
(Sigma).
[0127] Results showed that all these sera had lower binding to V6
than the wt MFE-23::CPG2 (FIG. 5, Table 2). Extrapolating the
maximum ELISA optical density signal for undiluted serum, the
antibody binding reductions in the patient group had the range
10.2-65.3%, with a median reduction of 45.1%. Rabbit anti-MFE-23
serum was used to detect the MFE-23 domains of wt and V6 fusion
proteins. As each CPG2 variant is linked to an MFE-23 sFv,
equimolar concentrations of the fusion proteins should have
equivalent anti-MFE-23 responses. The anti-MFE-23 binding responses
for the two fusion proteins varied by only 5.8%, a difference
within the limits of ELISA experimental error.
2TABLE 2 Percentage reduction of 15 ADEPT patient sera binding to
V6 compared to wt MFE-23::CPG2 determined by ELISA. Rabbit anti-MFE
serum is directed against the antibody domain of the fusion
proteins and acts as a negative control. Decrease in Serum antibody
binding (%) A1 30.1 A3 65.3 A4 13.3 A8 45.1 A11 62.0 A12 48.7 A13
57.6 A14 56.0 A15 25.5 A16 56.7 A17 20.1 A18 10.2 A19 51.5 A20 14.9
A21 30.2 Rabbit 5.8 anti-MFE
Example 2
Glycosylation of CPG Improves Retention of Fusion Proteins in
Tumours Despite Rapid Clearance from Normal Tumours
[0128] Although radiolabeled fusion protein of MFE-23::CPG2
expressed in E.coli has been shown to be promising candidate for
ADEPT if favorable enzyme delivery is established (Bhatia et al,
Int. J. Cancer 85 571-577, 2000), the yields obtained with this
bacterially expressed product were too low for developing a
clinical product. Therefore, the present inventors have
investigated expression in yeast Pichia pastoris. The Pichia
pastoris expressed product was constructed with tags for
identification and expression. Experiments performed with the
Pichia pastoris expressed fusion proteins led to two unexpected
findings:
[0129] a) that the glycosylated fusion proteins were retained in
active form in the tumour, despite rapid clearance from normal
tissues (described in the present Example);and
[0130] b) that the presence of C-terminal tags reduced
immunogenicity in animal models (described in Example 3).
[0131] 2.1 Glycosylation
[0132] Oligosaccharides were identified by collision induced
disassociation mass spectrometry (CID) of trypsinated fragments of
MFE-23::CPG2 gly-his (Pichia pastoris expressed MFE-23::CPG2 fusion
protein with a C-terminal hexahistidine tag).
[0133] There are three potential N-glycosylation sites on CPG2, CID
showed that only two of the three sites are glycosylated by Pichia
pastoris.Asn 222--Glycosylated, mostly mannose 5-13 chains Asn
264--Not glycosylated (not solvent exposed) Asn 272--Glycosylated,
mostly mannose 8-10 chains Some O-linked glycosylation (a maximum
of five mannose) is present on the MFE moiety of
MFE-23::CPG2gly-his.
[0134] 2.2 Pharmacokinetics & Biodistribution of
MFE::CPG2gly-his in Mice
[0135] Nude mice bearing LS174T xenografts were injected i.v. with
the fusion protein (25 units per mouse). Blood samples were taken
at different times after injection. Plasma and tissues were assayed
for CPG2 activity as follows:--CPG2 activity in tumor and normal
tissues was measured by in-vitro turnover of the substrate
methotrexate (MTX) by localised enzyme and measurement of the
metabolite peak by HPLC. Briefly, a calibration curve for each
tissue was constructed by incubating the relevant tissue (taken
from untreated mouse) with varying concentrations of CPG2 and a
fixed concentration of methotrexate and analysing the solution by
HPLC to give a standard line for CPG2 concentration v. metabolite
peak area formed. Tissue homogenates were prepared in assay buffer
(PBS+Zinc Chloride) w/v 20% and diluted further as appropriate and
incubated with methotrexate. The reaction was stopped by addition
of ice cold methanol (1:1). The supernatant was analysed by
HPLC.
[0136] 2.3 Clearance
[0137] Results for plasma clearance of MFE-CPG2gly-his in
comparison to those obtained with a chemical conjugate of
monoclonal anti-CEA with CPG2 (A5CP) are shown in FIG. 6. Rapid
clearance of MFE::CPG2gly-his is demonstrated.
[0138] 2.4 Biodistribution of MFE-CPG2gly-his
[0139] To assess CPG2 activity in enzyme activity in LS174T
xenografted nude mice, tumour, liver. kidney, lung and spleen were
collected from 4 mice per time point at 2, 4 and 6 hours after
intravenous injection of MFE-23::CPG2 gly-his fusion protein and
enzyme activity was assayed in tissue extracts. Results, shown in
FIG. 7, indicate that, despite rapid plasma clearance, enzyme
activity persists in the tumours. In addition, selective
localisation in the tumour occurs at much earlier time points than
observed with the A5B7-F(ab')2-CPG2 conjugate. Rapid plasma
clearance in conjunction with high levels of CPG2 activity
retention in tumours resulted in tumour to plasma ratios of 163:1
at 6 hrs after fusion protein injection. Tumour to liver, kidney,
lung and spleen ratios at 6 hrs post injection were 254,245, 158
and 160 respectively(FIG. 8).
[0140] 2.5 MFE-23::CPG2gly-his and MFE-23::CPG2gly-myc-his Remain
Intact in Tumour.
[0141] In addition to HPLC analysis of CPG2 enzyme activity in
excised tissue (FIG. 7), the integrity of the enzymatically active
material was tested to demonstrate that enzyme activity was due to
MFE-23::CPG2 which had remained intact in the tumour.
[0142] .sup.125I radiolabelled MFE-23::CPG2gly-his or
MFE-23::CPG2gly-myc-his was injected intravenously to nude
mice-bearing LS 174T human colorectal tumour xenografts. Four hours
later, the mice were sacrificed and the tumours were removed,
homogenised and subjected to SDS-PAGE. Radiolabelled material was
visualised by autoradiography. This demonstrated that
.sup.125I-MFE-23::CPG2 gly in the tumour had the same molecular
weight profile as .sup.125I-MFE-23::CPG2 gly prior to injection,
indicating stability in vivo.
[0143] 2.6 Relative Stability in Vivo
[0144] Effective targeted therapy relies on efficient antibody
retention in tumour after clearance from normal tissue and is
primarily influenced by the molecular size, stability and
functional affinity of the antibody. Molecular size determines the
circulating half-life of the antibody and, due to the dynamic
recirculation between blood and tumour, ultimately controls the
uptake and residence time in tumour. Large antibodies show better
tumour uptake and can deliver prolonged therapy but are impractical
due to their long circulating half-life. By contrast, small
antibodies show the perfect clearance pattern but are not retained
in tumour long enough to allow effective therapy. Ideally, the
therapeutic window would be extended by improving stability and
affinity. However, due to the obvious influence of molecular size
it is difficult to assess the isolated role of stability and
affinity on retention. One way of assessing retention, that is not
related to molecular size is to compare the area under the
time-uptake curve for the tumour-specific antibody with that of a
nonspecific antibody that has the same characteristic clearance
from blood. We have done this by fitting a bi-exponential function
to the blood data from the specific antibody. This function may
then be used along with a simple mathematical model, that assumes
recirculation between blood and tumour is caused only by a
concentration gradient between them, to simulate the equivalent
time-uptake curve for a non-specific antibody. The area under each
curve is obtained by integrating to infinity with respect to time
and the retention may be assessed by ratio of this integral for the
specific relative to the nonspecific antibody. This ratio is 64.5
for the glycosylated fusion protein (FIG. 9A) compared to only 4.4
for the non-glycosylated fusion protein (FIG. 9B). Therefore, we
estimate a potential 15-fold increase in therapeutic efficacy with
the glycosylated product.
[0145] 2.7 Therapy Studies Show Efficacy With MFE-23::CPG2gly-his
and MFE-23::CPG2gly-myc-his Fusion Proteins
[0146] Mice were injected with fusion protein (25 units per mouse)
i.v. when the tumours reached 0.1-0.2 cm.sup.3 and were in
exponential growth. The prodrug was given .times.3 over 2 hrs
between 4 and 6 hours after fusion protein injection at 90 mg/kg
per mouse i. p. Different control groups included fusion protein
alone (25 units/mouse), prodrug alone (90 mg/kg.times.3) and a no
treatment control group. Tumours were measured on day one prior to
treatment and subsequently on 3.sup.rd or 4.sup.th day until tumour
volume reached 2 cm.sup.3. The measurements were carried out in
three dimensions (length, width and height) and the tumour volume
estimated as length.times.width.times.height divided by 2. The mean
tumour volume (+/-sem) is plotted against days after treatment. The
fusion proteins in combination with bis-iodo prodrug showed good
growth delay of the tumour (see FIGS. 10A & 10B).
[0147] 2.8 Toxicity Studies
[0148] Mice were weighed prior to treatment and then .times.2
weekly. Weight % relative to day 1 was calculated for each group of
mice. Minimal toxicity was observed, see FIG. 11A for
MFE-23::CPG2gly-myc-his and FIG. 11B for MFE-23::CPG2 gly-his.
Example 3
Tagging the CPG2 Protein Reduces Immunogenicity
[0149] This example demonstrates that tagging of CPG2 with his or
myc-his results in reduced immunogenicity. In particular,
MFE-23::CPG2 gly-myc-his has very low immunogenicity.
[0150] 3.1 Immunogenicity Assay
[0151] Balb/C mice (6-8 week old females) were injected with the
following fusion proteins (50 ug protein per mouse i.p) at one
month intervals.
[0152] 1. MFE-23::CPG2 gly-myc-his (P. pastoris)
[0153] 2. MFE-23::CPG2gly-his (P. pastoris)
[0154] 3. MFE-23::CPG2-his (E. coli)
[0155] 4. MFE-23::CPG2 (E. coli).
[0156] Blood was collected from mice at 14 days post each
immunisation. Bloods were tested for mouse anti-CPG2 antibodies by
standard ELISA procedures. Briefly, 96-well microtitre plates were
coated with 100 .mu.l of CPG2 (10 .mu.g/ml in coating buffer)
overnight at 4.degree. C. Wells were blocked with 250 .mu.l of 3%
BSA for 1 hour and washed with PBS followed by distilled water.
Mouse sera (.times.100 dilution) were incubated in duplicate for 1
hour at RT. Wells were washed with PBS/Tween followed by distilled
water and incubated with sheep anti-mouse peroxidase antibody (10
.mu.l/well at 1/500dilution) for one hour. After washing, wells
were incubated with substrate (100 .mu.l /well) for 5 minutes for
colour to develop. The reaction was stopped by addition of 4M HCl.
The plate was read at optical density (O.D.)490 nm. SB43gal, a
mouse monoclonal anti-CPG2 antibody, was used as a positive control
and normal mouse serum was used as a negative control for ELISA
reactions. O.D.'s were analysed statistically using a
non-parametric test (Mann-Whitney U-test). Results are shown in
table 3. (O.D.--optical density, Fp--MFE-23::CPG2 fusion protein,
positive control--SB43gal, negative control--normal mouse serum).
Results are shown for 10 mice for each fusion protein.
[0157] 1. After the first immunisation there was no detectable
immune response to any of the MFE-23::CPG2 fusion proteins.
[0158] 2. After the second immunisation there was a detectable
immune response to the E.coli expressed MFE-23::CPG2 with no tag
(no.4 above) but not to any of the other constructs (nos 1-3
above). This difference was significant (p<0.001).
[0159] 3. After the third immunisation there was a strong response
to MFE-23::CPG2 with no tag, a weaker response to the -his tagged
MFE-23::CPG2s (P. pastoris and E coli being similar) and a very low
response to the -myc-his tagged MFE-23::CPG2 (see table 3 for
details). The differences were significant (p<0.001).
[0160] 4. After the fourth immunisation there were stronger
responses to the -his tagged MFE-23::CPG2s (P. pastoris>E .coli)
but still a very low response to the -myc-his tagged MFE-23::CPG2
(see table 3 for details). The difference between the -myc-his
tagged fusion protein and the no tagged fusion protein was
significant (p<0.001).
3TABLE 3 Plate coated with CPG2 Mouse anti-CPG2 response after 1st
immunisation Neg- Fpgly- Positive ative myc-his Fpgly-his e.
coli-his e. coli no tag O.D. 0.468 0.05 -0.1 -0.103 0.02 -0.069
-0.066 -0.095 -0.129 -0.098 -0.068 -0.091 -0.076 -0.046 -0.07 -0.08
-0.087 -0.071 -0.058 -0.038 0.022 -0.031 -0.091 -0.077 -0.073
-0.068 -0.094 -0.081 -0.044 0.017 -0.083 -0.088 0.019 -0.062 -0.041
-0.104 -0.052 -0.098 -0.054 -0.05 -0.004 -0.103 Mouse anti-CPG2
response after 2nd immunisation. Neg- Fpgly- Positive ative myc-his
Fpgly-his e. coli-his e. coli no tag O.D. 0.519 0.024 0.011 0.071
0.002 0.277 -0.033 -0.034 -0.026 0.308 -0.055 -0.035 0.011 0.198
0.033 -0.012 0.024 0.092 -0.017 0.05 -0.025 0.228 -0.012 -0.028
0.083 0.315 -0.01 -0.056 -0.009 0.232 -0.03 -0.041 0.078 0.313
-0.003 -0.043 0.023 -0.015 -0.023 -0.027 0.034 0.116 Mouse
anti-CPG2 response after 3rd immunisation Fpgly- positive negative
myc-his Fpgly-his e. coli-his e. coli no tag O.D. 1.167 0.02 0.019
0.897 0.801 1.709 0.222 0.514 1.4 1.618 0.028 0.095 0.794 1.374
0.005 0.98 1.436 1.289 0.015 1.67 1.19 1.904 0.02 0.454 1.344 1.722
0.029 0.984 0.952 1.884 0.021 0.791 1.202 1.775 0.039 0.55 0.86
1.077 0.025 1.416 1.523 1.454 Mouse anti-CPG2 response after 4th
immunisation Fpgly- positive negative myc-his Fpgly-his e. coli-his
e. coli-no tag O.D. 0.91 0.005 0.037 0.565 1.156 1.293 0.738 0.691
1.064 1.316 0.058 0.198 1.14 1.188 0.038 1.591 1.14 0.765 0.09
1.182 0.934 1.208 0.244 1.463 1.011 1.415 0.13 1.509 1.17 1.484
0.314 0.931 0.9 1.116 0.083 1.235 0.412 1.389 0.109 1.202 0.693
1.198 Negative numbers are below detection limits.
[0161] Imune response to E. coli and P. pastoris produced
MFE-23::CPG2 with different tags
[0162] In conclusion, there is a difference in immunogenicity
between the tagged and non-tagged fusion proteins; -his tag being
slightly effective in reducing the immune response and -myc-his tag
being very effective.
[0163] The reduction in immunogenicity is apparently not due to
glycosylation as there is no significant difference between the
immune response to MFE-23::CPG2-his tagged fusion proteins from
E.coli (not glycosylated) and P. pastoris (glycosylated).
[0164] 3.2 Molecular Dynamic Modelling
[0165] Molecular dynamic modelling was used to simulate the
interaction of His-tags and Myc-tags with the CPG2 molecule. The
results are shown in FIGS. 12, 13 and 14. FIG. 12 shows that a
charged histidine residue in the hexa-His tag may interact with a
residue (residue 163) from the epitope KEYGVRD(residues 157-163).
Such interaction would explain the reduced immunogenicity seen when
such tags are used. FIG. 13 shows that an uncharged histidine
residue in the hexa-His tag may interact with a residue (residue
K339) from the epitope EGGKKLVDK(residues 331-339). FIG. 14 shows
that an a glutamate residue in the Myc tag may interact with a
residue (residue K339) from the epitope EGGKKLVDK(residues
331-339), The modelling supports the observation that the tags
reduce immunogenicity.
Sequence CWU 1
1
21 1 8 PRT Pseudomonas sp. 1 Lys Ile Lys Gly Arg Gly Gly Lys 1 5 2
7 PRT Pseudomonas sp. 2 Lys Glu Tyr Gly Val Arg Asp 1 5 3 5 PRT
Pseudomonas sp. 3 Lys Leu Ala Asp Tyr 1 5 4 4 PRT Pseudomonas sp. 4
Gly Ala Gly Lys 1 5 9 PRT Pseudomonas sp. 5 Glu Gly Gly Lys Lys Leu
Val Asp Lys 1 5 6 5 PRT Pseudomonas sp. 6 Tyr Gly Val Arg Asp 1 5 7
415 PRT Pseudomonas sp. 7 Met Arg Pro Ser Ile His Arg Thr Ala Ile
Ala Ala Val Leu Ala Thr 1 5 10 15 Ala Phe Val Ala Gly Thr Ala Leu
Ala Gln Lys Arg Asp Asn Val Leu 20 25 30 Phe Gln Ala Ala Thr Asp
Glu Gln Pro Ala Val Ile Lys Thr Leu Glu 35 40 45 Lys Leu Val Asn
Ile Glu Thr Gly Thr Gly Asp Ala Glu Gly Ile Ala 50 55 60 Ala Ala
Gly Asn Phe Leu Glu Ala Glu Leu Lys Asn Leu Gly Phe Thr 65 70 75 80
Val Thr Arg Ser Lys Ser Ala Gly Leu Val Val Gly Asp Asn Ile Val 85
90 95 Gly Lys Ile Lys Gly Arg Gly Gly Lys Asn Leu Leu Leu Met Ser
His 100 105 110 Met Asp Thr Val Tyr Leu Lys Gly Ile Leu Ala Lys Ala
Pro Phe Arg 115 120 125 Val Glu Gly Asp Lys Ala Tyr Gly Pro Gly Ile
Ala Asp Asp Lys Gly 130 135 140 Gly Asn Ala Val Ile Leu His Thr Leu
Lys Leu Leu Lys Glu Tyr Gly 145 150 155 160 Val Arg Asp Tyr Gly Thr
Ile Thr Val Leu Phe Asn Thr Asp Glu Glu 165 170 175 Lys Gly Ser Phe
Gly Ser Arg Asp Leu Ile Gln Glu Glu Ala Lys Leu 180 185 190 Ala Asp
Tyr Val Leu Ser Phe Glu Pro Thr Ser Ala Gly Asp Glu Lys 195 200 205
Leu Ser Leu Gly Thr Ser Gly Ile Ala Tyr Val Gln Val Asn Ile Thr 210
215 220 Gly Lys Ala Ser His Ala Gly Ala Ala Pro Glu Leu Gly Val Asn
Ala 225 230 235 240 Leu Val Glu Ala Ser Asp Leu Val Leu Arg Thr Met
Asn Ile Asp Asp 245 250 255 Lys Ala Lys Asn Leu Arg Phe Asn Trp Thr
Ile Ala Lys Ala Gly Asn 260 265 270 Val Ser Asn Ile Ile Pro Ala Ser
Ala Thr Leu Asn Ala Asp Val Arg 275 280 285 Tyr Ala Arg Asn Glu Asp
Phe Asp Ala Ala Met Lys Thr Leu Glu Glu 290 295 300 Arg Ala Gln Gln
Lys Lys Leu Pro Glu Ala Asp Val Lys Val Ile Val 305 310 315 320 Thr
Arg Gly Arg Pro Ala Phe Asn Ala Gly Glu Gly Gly Lys Lys Leu 325 330
335 Val Asp Lys Ala Val Ala Tyr Tyr Lys Glu Ala Gly Gly Thr Leu Gly
340 345 350 Val Glu Glu Arg Thr Gly Gly Gly Thr Asp Ala Ala Tyr Ala
Ala Leu 355 360 365 Ser Gly Lys Pro Val Ile Glu Ser Leu Gly Leu Pro
Gly Phe Gly Tyr 370 375 380 His Ser Asp Lys Ala Glu Tyr Val Asp Ile
Ser Ala Ile Pro Arg Arg 385 390 395 400 Leu Tyr Met Ala Ala Arg Leu
Ile Met Asp Leu Gly Ala Gly Lys 405 410 415 8 11 PRT Artificial
Sequence Description of Artificial Sequence myc tag 8 Glu Gln Lys
Leu Ile Ser Glu Glu Asp Leu Asn 1 5 10 9 27 PRT Artificial Sequence
Description of Artificial Sequence myc-his tag 9 Ala Ala Ala Ser
Phe Leu Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu 1 5 10 15 Asn Ser
Ala Val Asp His His His His His His 20 25 10 7 PRT Artificial
Sequence Description of Artificial Sequence Hybrid sequence 10 Tyr
Glu Tyr Gly Val Met Lys 1 5 11 7 PRT Artificial Sequence
Description of Artificial Sequence Humanised sequence 11 Tyr Glu
Val Gly Met Met Lys 1 5 12 5 PRT Artificial Sequence Description of
Artificial Sequence Hybrid sequence 12 Arg Asn Ser Asp Tyr 1 5 13 5
PRT Artificial Sequence Description of Artificial Sequence
Humanised sequence 13 Arg Asn Ser Asp Arg 1 5 14 7 PRT Artificial
Sequence Description of Artificial Sequence CPG2 variant 14 Ala Glu
Tyr Gly Val Arg Asp 1 5 15 7 PRT Artificial Sequence Description of
Artificial Sequence CPG2 variant 15 Lys Ala Tyr Gly Val Arg Asp 1 5
16 7 PRT Artificial Sequence Description of Artificial Sequence
CPG2 variant 16 Lys Glu Ala Gly Val Arg Asp 1 5 17 7 PRT Artificial
Sequence Description of Artificial Sequence CPG2 variant 17 Lys Glu
Tyr Ala Val Arg Asp 1 5 18 7 PRT Artificial Sequence Description of
Artificial Sequence CPG2 variant 18 Lys Glu Tyr Gly Ala Arg Asp 1 5
19 7 PRT Artificial Sequence Description of Artificial Sequence
CPG2 variant 19 Lys Glu Tyr Gly Val Ala Asp 1 5 20 7 PRT Artificial
Sequence Description of Artificial Sequence CPG2 variant 20 Lys Glu
Tyr Gly Val Arg Ala 1 5 21 4 PRT Artificial Sequence Description of
Artificial Sequence CPG2 variant 21 Ala Ala Gly Lys 1
* * * * *